Ascletis Pharma Inc (2VJ) - Net Assets
Based on the latest financial reports, Ascletis Pharma Inc (2VJ) has net assets worth €1.87 Billion EUR (≈ $2.18 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.00 Billion ≈ $2.33 Billion USD) and total liabilities (€129.00 Million ≈ $150.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Ascletis Pharma Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.87 Billion |
| % of Total Assets | 93.54% |
| Annual Growth Rate | 21.68% |
| 5-Year Change | -34.06% |
| 10-Year Change | N/A |
| Growth Volatility | 102.48 |
Ascletis Pharma Inc - Net Assets Trend (2016–2024)
This chart illustrates how Ascletis Pharma Inc's net assets have evolved over time, based on quarterly financial data. Also explore Ascletis Pharma Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Ascletis Pharma Inc (2016–2024)
The table below shows the annual net assets of Ascletis Pharma Inc from 2016 to 2024. For live valuation and market cap data, see 2VJ company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.97 Billion ≈ $2.30 Billion |
-16.05% |
| 2023-12-31 | €2.34 Billion ≈ $2.74 Billion |
-7.79% |
| 2022-12-31 | €2.54 Billion ≈ $2.97 Billion |
-6.93% |
| 2021-12-31 | €2.73 Billion ≈ $3.19 Billion |
-8.47% |
| 2020-12-31 | €2.98 Billion ≈ $3.49 Billion |
-10.31% |
| 2019-12-31 | €3.32 Billion ≈ $3.89 Billion |
-3.01% |
| 2018-12-31 | €3.43 Billion ≈ $4.01 Billion |
+294.03% |
| 2017-12-31 | €869.83 Million ≈ $1.02 Billion |
+112.63% |
| 2016-12-31 | €409.08 Million ≈ $478.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ascletis Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 138372900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €3.44 Billion | 175.04% |
| Total Equity | €1.97 Billion | 100.00% |
Ascletis Pharma Inc Competitors by Market Cap
The table below lists competitors of Ascletis Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hunan Boyun New Materials Co Ltd
SHE:002297
|
$2.05 Billion |
|
OCADO GROUP SP.ADR 1/2
F:0OC1
|
$2.05 Billion |
|
DCM Shriram Limited
NSE:DCMSHRIRAM
|
$2.06 Billion |
|
Bausch Health Companies Inc
TO:BHC
|
$2.06 Billion |
|
Rendong Holdings Co Ltd
SHE:002647
|
$2.05 Billion |
|
HENSOLDT AG UNSP. ADS
F:HAG0
|
$2.05 Billion |
|
Electra Ltd
TA:ELTR
|
$2.05 Billion |
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
$2.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ascletis Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,342,066,000 to 1,966,162,000, a change of -375,904,000 (-16.1%).
- Net loss of 300,936,000 reduced equity.
- Share repurchases of 98,531,000 reduced equity.
- Other factors increased equity by 23,563,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-300.94 Million | -15.31% |
| Share Repurchases | €98.53 Million | -5.01% |
| Other Changes | €23.56 Million | +1.2% |
| Total Change | €- | -16.05% |
Book Value vs Market Value Analysis
This analysis compares Ascletis Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.86x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.29x to 0.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.53 | €1.75 | x |
| 2018-12-31 | €3.06 | €1.75 | x |
| 2019-12-31 | €3.00 | €1.75 | x |
| 2020-12-31 | €2.71 | €1.75 | x |
| 2021-12-31 | €2.51 | €1.75 | x |
| 2022-12-31 | €2.34 | €1.75 | x |
| 2023-12-31 | €2.25 | €1.75 | x |
| 2024-12-31 | €2.04 | €1.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ascletis Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23455.65%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-15.31%) is below the historical average (-7.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -9.84% | -81.29% | 0.06x | 1.97x | €-54.04 Million |
| 2017 | -9.03% | -101.38% | 0.05x | 1.66x | €-113.63 Million |
| 2018 | -0.21% | -4.36% | 0.05x | 1.03x | €-350.00 Million |
| 2019 | -2.89% | -55.33% | 0.05x | 1.03x | €-428.39 Million |
| 2020 | -7.02% | -597.81% | 0.01x | 1.03x | €-507.41 Million |
| 2021 | -7.29% | -258.88% | 0.03x | 1.04x | €-471.92 Million |
| 2022 | -12.40% | -582.07% | 0.02x | 1.05x | €-568.83 Million |
| 2023 | -6.18% | -255.70% | 0.02x | 1.06x | €-378.92 Million |
| 2024 | -15.31% | -23455.65% | 0.00x | 1.08x | €-497.55 Million |
Industry Comparison
This section compares Ascletis Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $493,888,592
- Average return on equity (ROE) among peers: -68.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ascletis Pharma Inc (2VJ) | €1.87 Billion | -9.84% | 0.07x | $2.05 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory … Read more